<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endobronchial brachytherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endobronchial brachytherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endobronchial brachytherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Henri G Colt, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Feller-Kopman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Brachytherapy refers to the placement of a radioactive source within or in close proximity to a malignancy in order to provide high doses of radiation in close proximity to the tumor [<a href="#rid1">1,2</a>]. Endobronchial brachytherapy is largely a palliative therapy for the treatment of locally advanced non-small cell lung cancer (NSCLC) involving the airway. However, the need for this technique has declined largely due to the expansion of other effective and less costly bronchoscopic ablative techniques including neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, argon plasma coagulation, electrocautery, and cryotherapy. </p><p>The use of endobronchial brachytherapy for the treatment of NSCLC will be reviewed here. Other interventional treatment modalities, such as airway stents, bronchoscopic laser resection, endobronchial electrocautery, cryotherapy, and argon plasma coagulation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4403.html" rel="external">"Airway stents"</a> and  <a class="medical medical_review" href="/z/d/html/4392.html" rel="external">"Bronchoscopic laser in the management of airway disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4396.html" rel="external">"Endobronchial electrocautery"</a> and  <a class="medical medical_review" href="/z/d/html/4407.html" rel="external">"Bronchoscopic cryotechniques in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4405.html" rel="external">"Bronchoscopic argon plasma coagulation in the management of airway disease in adults"</a>.)</p><p class="headingAnchor" id="H1056560151"><span class="h1">TECHNIQUE</span><span class="headingEndMark"> — </span>The major goal of endobronchial brachytherapy (EBBT) is a reduction in tumor size so that airway symptoms can be relieved. For patients suitable for EBBT (see <a class="local">'Patient selection'</a> below), a flexible bronchoscope is typically used to place a radioactive source (usually Iridium-192) within or in close proximity to the target endobronchial lesion (usually malignancy) [<a href="#rid3">3-7</a>]. Compared with external beam radiation therapy (EBRT), local radiation is provided to the lesion with the intent of sparing the tissues in the pathway of external beam. </p><p class="headingAnchor" id="H1056560311"><span class="h2">Bronchoscopy</span><span class="headingEndMark"> — </span>While in the past, rigid bronchoscopy was used [<a href="#rid8">8</a>], flexible bronchoscopy is the typical modality of choice for EBBT. Using a flexible bronchoscope, a polyethylene catheter with a radiopaque wire is passed transnasally (through a side port or alongside the bronchoscope) and placed in the desired position within the airway under direct visualization. The catheter position is verified fluoroscopically. The bronchoscope is removed and the catheter is secured to the nose of the patient. Additional reverification of the position with a plain chest radiograph can be performed, if necessary, before removing the "dummy seeds" and loading the catheter with a radioactive source (“afterloading”). Afterloading is usually performed with a remote afterloading device to minimize radiation exposure to providers, but can be performed manually if needed. </p><p>Occasionally the catheter containing the radioactive seed is not centered inside the airway and lies directly adjacent to the airway wall. In such cases, the bronchoscopist can use centering devices such as balloons, cages, or sheaths, to maintain the radioactive source within the center of the bronchial lumen and avoid dose inhomogeneity [<a href="#rid7">7</a>].</p><p>As for all endobronchial interventions, emergency airway equipment and a resuscitation cart are required for safety. </p><p class="headingAnchor" id="H1056560317"><span class="h2">Radiation type</span><span class="headingEndMark"> — </span>The dose rate of brachytherapy depends upon the energy and rate of decay of the radionuclide used, which, for endobronchial therapy is usually Iridium-192 [<a href="#rid3">3-7</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High dose rate (HDR)</strong> – HDR EBBT involves greater than 10 to 12 Gray (Gy)/hour, with the total dose ranging from 5 to 40 Gy, and the dose per session (fraction) varying from approximately 3 to 10 Gy. </p><p></p><p class="bulletIndent1">HDR EBBT is usually delivered in a series of dose fractions in order to optimize its effectiveness and minimize side effects. A wide variety of treatment schedules have been utilized; generally patients are treated no more than every one to two weeks because of the discomfort and logistical difficulties associated with more frequent bronchoscopies (ie, the catheter needs to be placed for each fraction of treatment).</p><p></p><p class="bulletIndent1">Computerized tomographic pre-planning usually determines the radiation dose administered. The American Brachytherapy Society now advocates using computed tomography (CT) planning with three-dimensional target definition for endobronchial brachytherapy rather than point definition in order to improve coverage and avoid underdosing [<a href="#rid9">9</a>]. The radiation isotope is moved in 5-mm increments ("dwell") positions along a pre-planned pathway for pre-specified dwell times in the catheter to optimize the dose. The process takes a few minutes. The catheter is then removed and the procedure repeated a few weeks later.</p><p></p><p class="bulletIndent1">HDR EBBT is more commonly employed than low dose rate (LDR) EBBT because treatment times are shorter, allowing it to be an outpatient procedure. Shorter catheter indwelling times also decrease the likelihood of catheter displacement, increase procedure efficiency, and reduce treatment cost. In addition, heavily shielded treatment rooms and the use of afterloading techniques for HDR EBBT equipment (ie, inserting the radionuclide into the bronchoscopically-placed catheter by means of a remotely controlled device) have made this a simpler and safer therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low dose rate (LDR)</strong> – LDR EBBT delivers less than 2 Gy/hour and a total dose of 1500 to 5000 Gy, given over a few days (usually up to three days) [<a href="#rid10">10,11</a>]. LDR EBBT requires manual manipulation of the radionuclide, 30 to 70 hours of continuous treatment, cumbersome radiation protection measures, and the catheter has to be left in place for the few days of administration. It is usually an inpatient procedure frequently complicated by catheter displacement, and is more costly than HDR EBBT. Thus, it has largely fallen out of favor. </p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span>Endobronchial brachytherapy (EBBT) is not a first line, curative, or sole therapy for lung cancer. It may be indicated for the palliative treatment of large obstructing central airway tumors (usually non-small cell lung cancer [NSCLC]) that are not amenable to surgical resection and/or external beam radiation. </p><p>EBBT has also been employed on rare occasions to treat recurrent airway NSCLC, metastatic airway tumors, early NSCLC that is limited to the airway, and non-malignant airway stenosis that has failed conventional therapy. </p><p>The need for this technique has declined due to the expansion of available ablative bronchoscopic therapies including laser, argon plasma coagulation, electrocautery, and cryotherapy. </p><p>Thus, patients with acute life-threatening symptoms of airway obstruction that need immediate relief <strong>can</strong> be treated with EBBT but only<strong> after</strong> other local ablative therapies or external beam radiation (EBRT) have been employed to shrink tumor size. (See  <a class="medical medical_review" href="/z/d/html/4392.html" rel="external">"Bronchoscopic laser in the management of airway disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4405.html" rel="external">"Bronchoscopic argon plasma coagulation in the management of airway disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4407.html" rel="external">"Bronchoscopic cryotechniques in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p>It is noteworthy that the American Brachytherapy Society recommends postponing endobronchial brachytherapy for patients during the coronavirus disease 2019 (COVID-19) pandemic because of safety concerns for health care professionals [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H1056560957"><span class="h2">Palliation of central obstructing airway tumors</span></p><p class="headingAnchor" id="H1141693395"><span class="h3">Patient and tumor characteristics</span><span class="headingEndMark"> — </span>High dose rate (HDR) EBBT can be used for the palliation of obstructive symptoms caused by large central airway tumors that are not amenable to surgical resection and/or external beam radiation [<a href="#rid9">9,13-15</a>]. It can also be used in this population when patients cannot tolerate or fail other local ablative therapies including neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, argon laser, or cryotherapy. Importantly, the types of cancer that are responsive to EBBT include biopsy-proven NSCLC or an extrathoracic malignancy metastatic to lung. Patients with small cell carcinoma or carcinoid are not typically suitable but EBBT has been used anecdotally when these tumors are refractory to multiple therapies.</p><p>Although specific criteria that render a patient or tumor suitable for EBBT varies, the following is generally accepted among most experts: </p><p class="bulletIndent1"><span class="glyph">●</span>The tumor (or tumor effect) should be visible by bronchoscopy. Thus, tumors located in the trachea, main stem, or lower lobe bronchi (ie, accessible to placement of a brachytherapy catheter, usually down to the third order bronchus) are generally considered suitable for EBBT. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The tumor can be either intrabronchial (intrinsic tumor of the airway) or extrabronchial (extrinsic compression of the airway) and may involve submucosal infiltration [<a href="#rid16">16,17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The degree of obstruction by the tumor has to be of sufficient size such that the catheter for delivery of the radiation source can be passed distally.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient should have sufficient life expectancy (usually more than three months) to derive palliative benefit. </p><p></p><p>Importantly, patients with acute life-threatening symptoms of airway obstruction that need immediate relief can be treated with EBBT but only<strong> after</strong> other local ablative therapies or external beam radiation (EBRT) have been employed to shrink tumor size. This is because ablative therapies and EBRT are immediate in their effect. In contrast, the effect of EBBT is usually delayed by two to three weeks and the initial response may cause edema and inflammation which can temporarily worsen airway compromise. (See <a class="local">'Contraindications'</a> below.)   </p><p class="headingAnchor" id="H1088789307"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Subjective and objective improvement following EBBT has been reported in 20 to 100 percent of patients [<a href="#rid10">10,18-20</a>]. The wide range likely reflects the variety of symptoms that existed prior to the procedure as well as the use of qualitative methods used during follow-up to assess response. Although most observational trials demonstrate improved symptoms, evidence is conflicting regarding true benefit when compared with other therapies. This was best demonstrated by a 2012 meta-analysis of 14 randomized trials involving 953 patients which reported that compared to external beam radiation (EBRT) and Nd:YAG laser therapy, there was no survival benefit associated with EBBT or EBBT in combination with chemotherapy [<a href="#rid14">14</a>]. Although some trials report that EBBT combined with EBRT may offer improved efficacy [<a href="#rid21">21-28</a>], the systematic review quoted above reported that the combination provided no greater symptom relief than EBRT alone [<a href="#rid14">14</a>]. Thus, while there are no high-quality studies directly comparing EBBT with EBRT, we agree with this analysis and suggest that for the majority of patients, EBBT should not be considered until patients have first undergone EBRT. (See  <a class="medical medical_review" href="/z/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p>There is limited evidence suggesting that endobronchial brachytherapy plus endobronchial laser therapy may be superior to endobronchial laser therapy alone [<a href="#rid5">5,29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/4392.html" rel="external">"Bronchoscopic laser in the management of airway disease in adults"</a>.)</p><p>Hemoptysis tends to improve most readily, with a greater than 90 percent response rate in many series [<a href="#rid15">15,31-36</a>]. Cough and dyspnea may improve less reliably, probably because they are frequently due to underlying conditions such as chronic obstructive pulmonary disease or radiation fibrosis. Additionally, EBBT may cause radiation bronchitis resulting in similar symptoms. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective observational series of 98 patients with locally advanced inoperable lung cancer treated with HDR EBBT, hemoptysis-free survival was 232 days, cough-free survival 140 days, and dyspnea-free survival was 173 days [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective study of 78 patients with malignant airway obstruction, 100 percent of patients with hemoptysis responded to HDR EBBT compared with 80 percent with post obstructive pneumonia, 57 percent with dyspnea, and 34 percent with cough [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 50 patients treated with HDR EBBT, hemoptysis was relieved in 24 of 28 patients (86 percent), breathlessness in 21 of 33 (64 percent), and cough in 9 of 18 patients (50 percent) [<a href="#rid32">32</a>]. These responses were maintained for four months.</p><p></p><p>Responses in tumor size and the degree of airway obstruction are most commonly evaluated by chest radiography and bronchoscopy. Some investigators use an obstruction score, but this has not been widely utilized [<a href="#rid29">29</a>]. According to some series, approximately 70 percent of patients have greater than 50 percent improvement in patency that persists for at least six months [<a href="#rid5">5,37</a>]. Different series have enrolled patients with different characteristics, making the results difficult to generalize due to probable selection bias. In addition, a significant number of patients in some reports refused subsequent bronchoscopy, potentially resulting in an overestimation of effectiveness.</p><p class="headingAnchor" id="H1056561023"><span class="h2">Other</span><span class="headingEndMark"> — </span>Data to support HDR EBBT in other populations are limited. However, clinicians with expertise have used EBBT to successfully treat patients with recurrent NSCLC or metastatic tumors of the airway, early NSCLC that is localized to the airway, as well as patients with positive resection margins or a stump recurrence following surgery. A few case reports describe benefit in patients with nonmalignant airway stenosis that has failed conventional therapy. </p><p class="headingAnchor" id="H1141693179"><span class="h3">Recurrent or metastatic airway tumors</span><span class="headingEndMark"> — </span>Limited retrospective data report benefit from HDR EBBT in patients with local recurrence of NSCLC in an airway stump following surgery, as well as in patients with lung cancer that is metastatic to the airway [<a href="#rid18">18,38</a>]. EBBT has also been employed postoperatively in patients found to have tumor at resection margins in an attempt to improve cure rates, or in patients with early stage lung cancer who can only tolerate sublobar resections [<a href="#rid38">38,39</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>An observational study of 175 patients with lung cancer who received HDR brachytherapy for persistent or recurrent cancer of the airway (mostly NSCLC) demonstrated symptomatic improvement in 115 patients (66 percent) [<a href="#rid18">18</a>]. Repeat bronchoscopy found that 78 percent of patients responded to EBBT, when a response to therapy was defined as at least 50 percent reopening of the normal lumen. Treatment-related complications were detected in only 19 patients (11 percent). A small number of patients received Nd:YAG laser therapy prior to EBBT which may have resulted in an over estimation of the response. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preliminary results in 14 patients who underwent sublobar resections for stage 1 NSCLC (ie, peripheral nodules) reported that intraoperative brachytherapy implants (manually placed by the surgeon) reduced local recurrence rates at seven months [<a href="#rid38">38</a>]. The impact on survival and long term recurrence was not reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an observational series of 34 patients with stage 1 NSCLC who had stump recurrence or positive margins following sublobar resection, HDR EBBT resulted in a disease free survival time of 17 months [<a href="#rid39">39</a>]. However, these rates may have been over estimated due to the inclusion of patients also treated with external beam radiation.   </p><p></p><p class="headingAnchor" id="H1141693173"><span class="h3">Airway tumors without extrabronchial spread</span><span class="headingEndMark"> — </span>Several observational studies report a beneficial response to HDR EBBT in patients with early NSCLC limited to the airway (eg, bronchial intraepithelial metaplasia, early endobronchial NSCLC without extrabronchial spread) who are not candidates for surgery or external beam radiation [<a href="#rid37">37,40-46</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 226 patients with NSCLC (97 percent had squamous cell carcinoma) without extrabronchial spread who were not candidates for surgery or external beam radiation therapy, HDR EBBT was associated with a complete endoscopic response rate of 94 percent at three months [<a href="#rid45">45</a>]. The two- and five-year overall survival rates were 57 and 29 percent, respectively, while the two- and five-year cancer-specific survival rates were 81 and 56 percent, respectively. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a similar population of 106 patients, HDR EBBT was associated with an overall five-year survival of 24 percent and a cause-specific five-year survival of 49 percent [<a href="#rid41">41</a>]. The five-year survival rates reflect the high rate of deaths not related to lung cancer in this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another observational study of 34 patients with local endobronchial NSCLC, at two years HDR EBBT was associated with a local control rate of 85 percent and a survival rate of 78 percent [<a href="#rid40">40</a>]. </p><p></p><p class="headingAnchor" id="H1056561103"><span class="h3">Nonmalignant airway stenosis</span><span class="headingEndMark"> — </span>Case reports suggest that in patients who have recurrent tracheal stenosis following repeated attempts at dilation and stenting, HDR EBBT (eg, a single 3 to 10-Gray [Gy] dose of Iridium-192) may be used to prevent the formation of granulation tissue and reduce the recurrence rate of restenosis [<a href="#rid47">47-50</a>]. In the largest series of 12 lung transplant patients, HDR EBBT (using a single dose application of 3 Gy of iridium-192) resulted in improved clinical status and lung function, and halved the rate of interventions needed for post-transplant tracheal stenosis [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Anastomotic complications'</a> and  <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Laryngotracheal stenosis'</a>.) </p><p class="headingAnchor" id="H1056560951"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Contraindications to endobronchial brachytherapy (EBBT) include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of fistulas between bronchi and other structures. EBBT in this setting increases the risk of viscus rupture and fatal hemorrhage. (See  <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Tracheoesophageal fistula'</a> and  <a class="medical medical_review" href="/z/d/html/6377.html" rel="external">"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of high-grade airway obstruction. Patients with significant airway compromise should be treated with bronchoscopic ablative techniques such as neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, argon plasma coagulation, electrocautery, stent insertion, or external beam radiation before brachytherapy, because the use of brachytherapy will not immediately shrink tumor size (maximal effect is after three weeks) and, in fact, may result in postradiation tissue edema and complete airway obstruction. (See  <a class="medical medical_review" href="/z/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are moribund or who have contraindications to bronchoscopy in general. (See  <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">"Flexible bronchoscopy in adults: Indications and contraindications", section on 'Contraindications'</a>.) </p><p></p><p>Relative contraindications include the following [<a href="#rid51">51-53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lesions in close proximity to large vessels (ie, at the anterior distal trachea, the orifice to the right upper lobe, the mid-distal left mainstem, or the carina between the left upper and lower lobes)</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant involvement of the major arteries</p><p class="bulletIndent1"><span class="glyph">●</span>Significant destruction of the bronchial wall</p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal invasion</p><p></p><p>These factors increase the risk of fistula formation and fatal hemorrhage, which are serious, life-threatening complications of EBBT. Computed tomography (CT), magnetic resonance imaging, or digital subtraction angiography may be helpful in assessing these factors prior to the procedure. (See <a class="local">'Complications'</a> below and  <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a> and  <a class="medical medical_review" href="/z/d/html/15663.html" rel="external">"Etiology of hemoptysis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6377.html" rel="external">"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula"</a>.)</p><p>Although small cell lung cancer or tumors other than non-small cell lung cancer (NSCLC) are not contraindications to EBBT per se, use of EBBT is anecdotal in patients with these tumors refractory to multiple therapies.</p><p class="headingAnchor" id="H5"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Most studies report that the complication rate of endobronchial brachytherapy (EBBT) is at least 5 percent but it can be as high as 40 percent [<a href="#rid31">31,33,51-54</a>]. Complications of EBBT can occur early (hours to days) or late (days to weeks). </p><p>A commercially available catheter is designed to facilitate centralization of the radioactive source within the endobronchial lumen during radiation delivery and may limit damage due to eccentric positioning of the dose-delivering catheter [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1056561370"><span class="h2">Early</span><span class="headingEndMark"> — </span>Early complications are infrequent and usually due to bronchoscopy or catheter insertion. Hemoptysis and catheter displacement are the most worrisome early complications. Other common early complications of bronchoscopy (eg, hypotension, bacteremia) are listed in the table  (<a class="graphic graphic_table graphicRef50348" href="/z/d/graphic/50348.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4400.html" rel="external">"Flexible bronchoscopy in adults: Indications and contraindications"</a>.)</p><p>Risk factors for early complications associated with EBBT have been reported and include hypertension, cardiac arrhythmias, and chronic obstructive pulmonary disease, as well as the presence of multiple risk factors and older age [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H1056561381"><span class="h2">Late</span><span class="headingEndMark"> — </span>Late complications are common and frequently include radiation bronchitis and airway stenosis. They can manifest with a cough or wheezing. Risk factors for these complications include large cell carcinoma, use of brachytherapy for curative intent, prior laser resection, and concurrent external beam radiation [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4331.html" rel="external">"Radiation-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/1644.html" rel="external">"Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients", section on 'Laryngotracheal stenosis'</a>.)</p><p>Massive hemoptysis and fistula formation (eg, tracheoesophageal or tracheal-aortic fistula) are particularly serious late complications of endobronchial brachytherapy. Tracheobronchial ulceration often precedes massive hemoptysis. Case series indicate that such adverse outcomes occur in up to 42 percent of patients [<a href="#rid5">5,6,16,18,51,52,56-62</a>]. Potential risk factors for these complications include use of EBBT to treat malignant involvement of the major arteries, lesions with significant destruction of the bronchial wall or with mediastinal invasion [<a href="#rid51">51-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4394.html" rel="external">"Evaluation and management of life-threatening hemoptysis"</a> and  <a class="medical medical_review" href="/z/d/html/15663.html" rel="external">"Etiology of hemoptysis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6377.html" rel="external">"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Endobronchial brachytherapy (EBBT) refers to the placement of a radioactive source within or in close proximity to a malignancy in order to provide high doses of radiation close to the tumor. The need of this technique has declined largely due to the expansion of other effective and less costly bronchoscopic ablative techniques including neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, argon plasma coagulation, and cryotherapy. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – EBBT is largely a palliative therapy for the treatment of locally advanced non-small cell lung cancer (NSCLC) involving the airway. Thus, the major goal of EBBT is a reduction in tumor size so that airway symptoms can be relieved. A flexible bronchoscope is typically used to place a radioactive source (usually Iridium-192) within or in close proximity to the target endobronchial lesion (usually malignancy). High dose rate (HDR) EBBT can be performed as an outpatient procedure and is more commonly used than low dose rate EBBT due to shorter treatment times and reduced cost. (See <a class="local">'Technique'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – HDR EBBT is not a first-line or curative therapy for lung cancer. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HDR EBBT is usually indicated for the palliative treatment of large obstructing central airway tumors (usually NSCLC) that are amenable to resection and/or external beam radiation. EBBT is typically not a sole therapy in this population and is often combined with bronchoscopic ablative therapies. (See <a class="local">'Patient selection'</a> above and <a class="local">'Palliation of central obstructing airway tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HDR EBBT has also been employed on rare occasions to treat recurrent airway NSCLC, metastatic airway tumors, early NSCLC that is limited to the airway, and nonmalignant tracheal stenosis that has failed conventional therapy. (See <a class="local">'Patient selection'</a> above and <a class="local">'Other'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – Contraindications to EBBT include the presence of fistulas between bronchi and other structures and high-grade airway obstruction. In addition, EBBT should not be performed in patients who are moribund or in whom there are contraindications to bronchoscopy in general. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Complications of EBBT are common (up to 40 percent), and typically occur days to weeks after the procedure. They include radiation bronchitis and airway stenosis as well as more worrisome complications including tracheal ulceration, fatal hemoptysis, and fistulous formation with surrounding structures. (See <a class="local">'Complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hilaris BS, Mastoras DA. Contemporary brachytherapy approaches in non-small-cell lung cancer. J Surg Oncol 1998; 69:258.</a></li><li><a class="nounderline abstract_t">Raben A, Mychalczak B. Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest. Chest 1997; 112:276S.</a></li><li><a class="nounderline abstract_t">Mendiondo OA, Dillon M, Beach LJ. Endobronchial brachytherapy in the treatment of recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1983; 9:579.</a></li><li><a class="nounderline abstract_t">Schray MF, McDougall JC, Martinez A, et al. Management of malignant airway obstruction: clinical and dosimetric considerations using an iridium-192 afterloading technique in conjunction with the neodymium-YAG laser. Int J Radiat Oncol Biol Phys 1985; 11:403.</a></li><li><a class="nounderline abstract_t">Schray MF, McDougall JC, Martinez A, et al. Management of malignant airway compromise with laser and low dose rate brachytherapy. The Mayo Clinic experience. Chest 1988; 93:264.</a></li><li><a class="nounderline abstract_t">Seagren SL, Harrell JH, Horn RA. High dose rate intraluminal irradiation in recurrent endobronchial carcinoma. Chest 1985; 88:810.</a></li><li><a class="nounderline abstract_t">Nag S, Kelly JF, Horton JL, et al. Brachytherapy for carcinoma of the lung. Oncology (Williston Park) 2001; 15:371.</a></li><li><a class="nounderline abstract_t">Nori D, Hilaris BS, Martini N. Intraluminal irradiation in bronchogenic carcinoma. Surg Clin North Am 1987; 67:1093.</a></li><li><a class="nounderline abstract_t">Stewart A, Parashar B, Patel M, et al. American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy 2016; 15:1.</a></li><li><a class="nounderline abstract_t">Villanueva AG, Lo TC, Beamis JF Jr. Endobronchial brachytherapy. Clin Chest Med 1995; 16:445.</a></li><li class="breakAll">Shaw, EG, McDougall, JC. Bronchoscopic brachytherapy. In: Bronchoscopy, Prakash, UBS (Eds), Raven Press, New York 1994. p.293-300.</li><li><a class="nounderline abstract_t">Mohindra P, Beriwal S, Kamrava M. Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic. Brachytherapy 2020; 19:390.</a></li><li><a class="nounderline abstract_t">Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e455S.</a></li><li><a class="nounderline abstract_t">Reveiz L, Rueda J-R, Cardona AF. Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2012; :CD004284.</a></li><li><a class="nounderline abstract_t">Goldberg M, Timotin E, Farrell T, et al. A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience. Brachytherapy 2015; 14:655.</a></li><li><a class="nounderline abstract_t">Allen MD, Baldwin JC, Fish VJ, et al. Combined laser therapy and endobronchial radiotherapy for unresectable lung carcinoma with bronchial obstruction. Am J Surg 1985; 150:71.</a></li><li><a class="nounderline abstract_t">Ofiara L, Roman T, Schwartzman K, Levy RD. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma. Chest 1997; 112:946.</a></li><li><a class="nounderline abstract_t">Kelly JF, Delclos ME, Morice RC, et al. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys 2000; 48:697.</a></li><li><a class="nounderline abstract_t">Taulelle M, Chauvet B, Vincent P, et al. High dose rate endobronchial brachytherapy: results and complications in 189 patients. Eur Respir J 1998; 11:162.</a></li><li><a class="nounderline abstract_t">Guarnaschelli JN, Jose BO. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience. J Palliat Med 2010; 13:981.</a></li><li><a class="nounderline abstract_t">Ozkok S, Karakoyun-Celik O, Goksel T, et al. High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients. Lung Cancer 2008; 62:326.</a></li><li><a class="nounderline abstract_t">Saito M, Yokoyama A, Kurita Y, et al. Treatment of roentogenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1996; 34:1029.</a></li><li><a class="nounderline abstract_t">Yokomise H, Nishimura Y, Fukuse T, et al. Long-term remission after brachytherapy with external irradiation for locally advanced lung cancer. Respiration 1998; 65:489.</a></li><li><a class="nounderline abstract_t">Hernandez P, Gursahaney A, Roman T, et al. High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation. Thorax 1996; 51:354.</a></li><li><a class="nounderline abstract_t">Saito M, Yokoyama A, Kurita Y, et al. Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy: second report. Int J Radiat Oncol Biol Phys 2000; 47:673.</a></li><li><a class="nounderline abstract_t">Huber RM, Fischer R, Hautmann H, et al. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997; 38:533.</a></li><li><a class="nounderline abstract_t">Langendijk H, de Jong J, Tjwa M, et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol 2001; 58:257.</a></li><li><a class="nounderline abstract_t">Stout R, Barber P, Burt P, et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000; 56:323.</a></li><li><a class="nounderline abstract_t">Speiser B, Spratling L. Intermediate dose rate remote afterloading brachytherapy for intraluminal control of bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1990; 18:1443.</a></li><li><a class="nounderline abstract_t">Shea JM, Allen RP, Tharratt RS, et al. Survival of patients undergoing Nd:YAG laser therapy compared with Nd:YAG laser therapy and brachytherapy for malignant airway disease. Chest 1993; 103:1028.</a></li><li><a class="nounderline abstract_t">de Aquino Gorayeb MM, Gregório MG, de Oliveira EQ, et al. High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment. Brachytherapy 2013; 12:471.</a></li><li><a class="nounderline abstract_t">Burt PA, O'Driscoll BR, Notley HM, et al. Intraluminal irradiation for the palliation of lung cancer with the high dose rate micro-Selectron. Thorax 1990; 45:765.</a></li><li><a class="nounderline abstract_t">Speiser BL, Spratling L. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993; 25:579.</a></li><li><a class="nounderline abstract_t">Chang LF, Horvath J, Peyton W, Ling SS. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer. Int J Radiat Oncol Biol Phys 1994; 28:589.</a></li><li><a class="nounderline abstract_t">Gollins SW, Burt PA, Barber PV, Stout R. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol 1994; 33:31.</a></li><li><a class="nounderline abstract_t">Pisch J, Villamena PC, Harvey JC, et al. High dose-rate endobronchial irradiation in malignant airway obstruction. Chest 1993; 104:721.</a></li><li><a class="nounderline abstract_t">Nori D, Allison R, Kaplan B, et al. High dose-rate intraluminal irradiation in bronchogenic carcinoma. Technique and results. Chest 1993; 104:1006.</a></li><li><a class="nounderline abstract_t">d'Amato TA, Galloway M, Szydlowski G, et al. Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. Chest 1998; 114:1112.</a></li><li><a class="nounderline abstract_t">Skowronek J, Piorunek T, Kanikowski M, et al. Definitive high-dose-rate endobronchial brachytherapy of bronchial stump for lung cancer after surgery. Brachytherapy 2013; 12:560.</a></li><li><a class="nounderline abstract_t">Marsiglia H, Baldeyrou P, Lartigau E, et al. High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma. Int J Radiat Oncol Biol Phys 2000; 47:665.</a></li><li><a class="nounderline abstract_t">Hennequin C, Bleichner O, Trédaniel J, et al. Long-term results of endobronchial brachytherapy: A curative treatment? Int J Radiat Oncol Biol Phys 2007; 67:425.</a></li><li><a class="nounderline abstract_t">Fuwa N, Kodaira T, Tachibana H, et al. Long-term observation of 64 patients with roentgenographically occult lung cancer treated with external irradiation and intraluminal irradiation using low-dose-rate iridium. Jpn J Clin Oncol 2008; 38:581.</a></li><li><a class="nounderline abstract_t">Sutedja G, Baris G, van Zandwijk N, Postmus PE. High-dose rate brachytherapy has a curative potential in patients with intraluminal squamous cell lung cancer. Respiration 1994; 61:167.</a></li><li><a class="nounderline abstract_t">Pérol M, Caliandro R, Pommier P, et al. Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy. Results of a pilot study. Chest 1997; 111:1417.</a></li><li><a class="nounderline abstract_t">Aumont-le Guilcher M, Prevost B, Sunyach MP, et al. High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients. Int J Radiat Oncol Biol Phys 2011; 79:1112.</a></li><li><a class="nounderline abstract_t">Wisnivesky JP, Yung RC, Mathur PN, Zulueta JJ. Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e263S.</a></li><li><a class="nounderline abstract_t">Kramer MR, Katz A, Yarmolovsky A, et al. Successful use of high dose rate brachytherapy for non-malignant bronchial obstruction. Thorax 2001; 56:415.</a></li><li><a class="nounderline abstract_t">Tscheikuna J, Disayabutr S, Kakanaporn C, et al. High dose rate endobronchial brachytherapy (HDR-EB) in recurrent benign complex tracheobronchial stenosis: experience in two cases. J Med Assoc Thai 2013; 96 Suppl 2:S252.</a></li><li><a class="nounderline abstract_t">Allen AM, Abdelrahman N, Silvern D, et al. Endobronchial brachytherapy provides excellent long-term control of recurrent granulation tissue after tracheal stenosis. Brachytherapy 2012; 11:322.</a></li><li><a class="nounderline abstract_t">Meyer A, Warszawski-Baumann A, Baumann R, et al. HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation. Strahlenther Onkol 2012; 188:1085.</a></li><li><a class="nounderline abstract_t">Khanavkar B, Stern P, Alberti W, Nakhosteen JA. Complications associated with brachytherapy alone or with laser in lung cancer. Chest 1991; 99:1062.</a></li><li><a class="nounderline abstract_t">Hara R, Itami J, Aruga T, et al. Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies. Cancer 2001; 92:2623.</a></li><li><a class="nounderline abstract_t">Hennequin C, Tredaniel J, Chevret S, et al. Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis. Int J Radiat Oncol Biol Phys 1998; 42:21.</a></li><li><a class="nounderline abstract_t">Zaric B, Perin B, Jovelic A, et al. Clinical risk factors for early complications after high-dose-rate endobronchial brachytherapy in the palliative treatment of lung cancer. Clin Lung Cancer 2010; 11:182.</a></li><li><a class="nounderline abstract_t">Nomoto Y, Ii N, Murashima S, et al. Endobronchial brachytherapy with curative intent: the impact of reference points setting according to the bronchial diameter. J Radiat Res 2017; 58:849.</a></li><li><a class="nounderline abstract_t">Bedwinek J, Petty A, Bruton C, et al. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992; 22:23.</a></li><li><a class="nounderline abstract_t">Lo TC, Beamis JF Jr, Weinstein RS, et al. Intraluminal low-dose rate brachytherapy for malignant endobronchial obstruction. Radiother Oncol 1992; 23:16.</a></li><li><a class="nounderline abstract_t">Mehta MP, Shahabi S, Jarjour NN, Kinsella TJ. Endobronchial irradiation for malignant airway obstruction. Int J Radiat Oncol Biol Phys 1989; 17:847.</a></li><li class="breakAll">Speiser, B, Spratling, L. High dose rate remove afterloading brachytherapy in the control of endobronchial carcinoma. In: Brachytherapy HDR and LDR, Martinez, AA, Orton, CG, Mould, RF (Eds), Nucletron Corp, Columbia, MD 1990. p.10.</li><li><a class="nounderline abstract_t">Sutedja G, Baris G, Schaake-Koning C, van Zandwijk N. High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24:551.</a></li><li><a class="nounderline abstract_t">Chawla M, Getzen T, Simoff MJ. Medical pneumonectomy: interventional bronchoscopic and endovascular management of massive hemoptysis due to pulmonary artery pseudoaneurysm, a consequence of endobronchial brachytherapy. Chest 2009; 135:1355.</a></li><li><a class="nounderline abstract_t">Matsumoto I, Oda M, Imagawa T, et al. Management of tracheobronchial ulceration induced by high-dose brachytherapy. Ann Thorac Surg 2009; 87:1301.</a></li></ol></div><div id="topicVersionRevision">Topic 4408 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9881944" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Contemporary brachytherapy approaches in non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9337304" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6853259" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endobronchial brachytherapy in the treatment of recurrent bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2579051" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of malignant airway obstruction: clinical and dosimetric considerations using an iridium-192 afterloading technique in conjunction with the neodymium-YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2448089" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of malignant airway compromise with laser and low dose rate brachytherapy. The Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2415306" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High dose rate intraluminal irradiation in recurrent endobronchial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11301833" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Brachytherapy for carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2442822" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intraluminal irradiation in bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26561277" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521699" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endobronchial brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8521699" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endobronchial brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32423787" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Proposed brachytherapy recommendations (practical implementation, indications, and dose fractionation) during COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649452" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Palliative endobronchial brachytherapy for non-small cell lung cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25983031" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2409829" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combined laser therapy and endobronchial radiotherapy for unresectable lung carcinoma with bronchial obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9377957" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020566" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9543287" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : High dose rate endobronchial brachytherapy: results and complications in 189 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666622" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482780" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High dose rate endobronchial brachytherapy in the management of lung cancer: response and toxicity evaluation in 158 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600085" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Treatment of roentogenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817967" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Long-term remission after brachytherapy with external irradiation for locally advanced lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733484" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837951" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low-dose-rate brachytherapy: second report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231677" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11230886" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10974381" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1695215" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intermediate dose rate remote afterloading brachytherapy for intraluminal control of bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7510598" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Survival of patients undergoing Nd:YAG laser therapy compared with Nd:YAG laser therapy and brachytherapy for malignant airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541114" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High-dose-rate brachytherapy in symptom palliation due to malignant endobronchial obstruction: a quantitative assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1701061" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraluminal irradiation for the palliation of lung cancer with the high dose rate micro-Selectron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8454476" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Remote afterloading brachytherapy for the local control of endobronchial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509330" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7533304" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7689945" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : High dose-rate endobronchial irradiation in malignant airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691481" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High dose-rate intraluminal irradiation in bronchogenic carcinoma. Technique and results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792585" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23850277" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Definitive high-dose-rate endobronchial brachytherapy of bronchial stump for lung cancer after surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837950" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : High-dose-rate brachytherapy as sole modality for early-stage endobronchial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17084547" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term results of endobronchial brachytherapy: A curative treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18723609" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term observation of 64 patients with roentgenographically occult lung cancer treated with external irradiation and intraluminal irradiation using low-dose-rate iridium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8047721" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High-dose rate brachytherapy has a curative potential in patients with intraluminal squamous cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9149603" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy. Results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20510543" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : High-dose-rate brachytherapy for non-small-cell lung carcinoma: a retrospective study of 226 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23649442" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnosis and treatment of bronchial intraepithelial neoplasia and early lung cancer of the central airways: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312413" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Successful use of high dose rate brachytherapy for non-malignant bronchial obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590050" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High dose rate endobronchial brachytherapy (HDR-EB) in recurrent benign complex tracheobronchial stenosis: experience in two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22381651" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Endobronchial brachytherapy provides excellent long-term control of recurrent granulation tissue after tracheal stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23104520" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : HDR brachytherapy: an option for preventing nonmalignant obstruction in patients after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2019157" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Complications associated with brachytherapy alone or with laser in lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745197" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Risk factors for massive hemoptysis after endobronchial brachytherapy in patients with tracheobronchial malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747815" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439194" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical risk factors for early complications after high-dose-rate endobronchial brachytherapy in the palliative treatment of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29106573" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endobronchial brachytherapy with curative intent: the impact of reference points setting according to the bronchial diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727125" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1736327" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Intraluminal low-dose rate brachytherapy for malignant endobronchial obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2777675" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endobronchial irradiation for malignant airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2777675" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endobronchial irradiation for malignant airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1383178" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : High dose rate brachytherapy in patients with local recurrences after radiotherapy of non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420204" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Medical pneumonectomy: interventional bronchoscopic and endovascular management of massive hemoptysis due to pulmonary artery pseudoaneurysm, a consequence of endobronchial brachytherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324186" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of tracheobronchial ulceration induced by high-dose brachytherapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
